Flu Season Rages: SHBAN Hand Sanitizer Is Superior to Most Alcohol Gels

  BioTech Medics, Inc., (PINKSHEETS: BMCS) distributors of SHBAN Alcohol Free Persistent Hand Sanitizer announces tips to help individuals combat the massive influenza outbreak. The Center for Disease Control (CDC) identified this flu season worse than normal. A new strain of stomach bug sweeping the globe is the Sydney norovirus.

Ever wondered why those who use alcohol gel hand sanitizers still get a cold or flu? Viruses are not germs! Alcohol gels with 60% or less alcohol have not been proven effective against some viruses unless an additional active ingredient is included.

The CDC and the World Health Organization (WHO) recommends the use of "persistent" hand sanitizers. Persistent activity is defined as the prolonged or extended antimicrobial activity that prevents or inhibits the proliferation or survival of microorganisms after application of the product. Alcohol gels alone don't work after they dry on your hands. So they are not "persistent" unless an additional ingredient is used to prolong antimicrobial activity. Source: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5116a1.htm

SHBAN is superior to alcohol gel hand sanitizers (without additives) because its FDA Class I "active ingredient" is "persistent" due to the fact SHBAN is long-lasting (up to 4 hours according to laboratory tests). SHBAN is a USA green product. Clinical tests have shown SHBAN's active ingredient inhibits various viruses.

SHBAN is gentle on your hands. SHBAN can be used on a cotton swab in your nostrils (don't use alcohol gels). 80% of viruses are inhaled from droplets from a contagious person's cough.

SHBAN is economical. One (1) ounce of SHBAN is equal to six (6) ounces of alcohol gel. SHBAN is available online: www.shban.com. Free shipping in the continental USA on quantities of 3 bottles or more if purchased online through February 2013.

According to a GIA Research: US Hand Sanitizer sales are may reach US$226.3 million by 2018. BioTech Medics Inc has signed a $5 million U.S. cross-marketing licensing non-exclusive contract for its patented SHBAN with LifeBionix, Inc.

The FDA has not evaluated the SHBAN statements above. SHBAN is not intended to diagnose, treat or cure any disease. Safe Harbor: Forward-Looking Statements: This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain uncertainties.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: Tom Wood Sr. V.P. Sales Phone: [phone]